Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Testosterone treatment in multiple sclerosis: a pilot study.

Sicotte NL, Giesser BS, Tandon V, Klutch R, Steiner B, Drain AE, Shattuck DW, Hull L, Wang HJ, Elashoff RM, Swerdloff RS, Voskuhl RR.

Arch Neurol. 2007 May;64(5):683-8.

PMID:
17502467
2.

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.

Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M.

Arch Neurol. 2009 Sep;66(9):1144-50. doi: 10.1001/archneurol.2009.174.

PMID:
19752305
3.

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.

Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.

BMC Neurol. 2006 May 23;6:19.

4.

Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.

Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.

Arch Neurol. 2005 Dec;62(12):1843-7.

PMID:
16344342
5.

Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.

Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N.

Arch Neurol. 2007 Aug;64(8):1157-61.

PMID:
17698706
6.

Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.

Pulizzi A, Rovaris M, Judica E, Sormani MP, Martinelli V, Comi G, Filippi M.

Arch Neurol. 2007 Aug;64(8):1163-8.

PMID:
17698707
7.

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group.

Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.

PMID:
19542262
8.

Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.

Zhao Y, Traboulsee A, Petkau AJ, Li D.

Neurology. 2008 Mar 25;70(13 Pt 2):1092-7. Epub 2007 Nov 14.

PMID:
18003938
9.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
10.

Gender change and its impact on the course of multiple sclerosis.

Reske D, Haupt WF, Petereit HF.

Acta Neurol Scand. 2006 May;113(5):347-9. Erratum in: Acta Neurol Scand. 2006 Aug;114(2):144. Haupt, WF [added]; Petereit, HF [added].

PMID:
16629772
11.

Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.

Battaglini M, Giorgio A, Stromillo ML, Bartolozzi ML, Guidi L, Federico A, De Stefano N.

J Neurol Sci. 2009 Jul 15;282(1-2):55-60. doi: 10.1016/j.jns.2009.02.322. Epub 2009 Mar 16.

PMID:
19286193
12.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
13.

Gender-related differences in MS: a study of conventional and nonconventional MRI measures.

Antulov R, Weinstock-Guttman B, Cox JL, Hussein S, Durfee J, Caiola C, Dwyer MG, Bergsland N, Abdelrahman N, Stosic M, Hojnacki D, Munschauer FE, Miletic D, Zivadinov R.

Mult Scler. 2009 Mar;15(3):345-54. doi: 10.1177/1352458508099479. Epub 2008 Nov 21.

PMID:
19028830
14.

Pilot study of minocycline in relapsing-remitting multiple sclerosis.

Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR.

Can J Neurol Sci. 2008 May;35(2):185-91.

PMID:
18574932
15.

Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis.

Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock-Guttman B, Garg N, Munschauer F, Zivadinov R.

Arch Neurol. 2006 Sep;63(9):1301-6.

PMID:
16966509
16.

Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.

Boster A, Hreha S, Berger JR, Bao F, Penmesta R, Tselis A, Endress C, Zak I, Perumal J, Caon C, Vazquez J, Tyler KL, Racke MK, Millis S, Khan O.

Arch Neurol. 2009 May;66(5):593-9. doi: 10.1001/archneurol.2009.31.

PMID:
19433659
17.

Impact of individual cognitive profile on visuo-motor reorganization in relapsing-remitting multiple sclerosis.

Gioia MC, Cerasa A, Liguori M, Passamonti L, Condino F, Vercillo L, Valentino P, Clodomiro A, Quattrone A, Fera F.

Brain Res. 2007 Sep 5;1167:71-9. Epub 2007 Jun 21.

PMID:
17689504
18.

Association between MRI parameters and the MS severity scale: a 12 year follow-up study.

Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F.

Mult Scler. 2009 May;15(5):632-7. doi: 10.1177/1352458509102617.

PMID:
19389751
19.

Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.

Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):407-14. Epub 2007 Jun 5.

PMID:
17550987
20.

Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis.

Cader S, Palace J, Matthews PM.

J Psychopharmacol. 2009 Aug;23(6):686-96. doi: 10.1177/0269881108093271. Epub 2008 Jul 17.

PMID:
18635705

Supplemental Content

Support Center